Alpha Cognition Inc. Research and Development Expense
Alpha Cognition Inc. (ACOG) reported Research and Development Expense of $2.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Alpha Cognition Inc. research and development expense for the quarter ending 2026-06-30 was $2.01M, a 394.63% increase year-over-year.
- Alpha Cognition Inc. research and development expense for the quarter ending 2026-03-31 was $1.10M, a 173.79% increase year-over-year.
- Alpha Cognition Inc. research and development expense for the quarter ending 2025-12-31 was $569.75K, a 45.24% decline year-over-year.
- Alpha Cognition Inc. research and development expense for the quarter ending 2025-09-30 was $573.59K, a 42.41% decline year-over-year.
- Alpha Cognition Inc. research and development expense for fiscal 2025 was $1.87M, a 52.35% decline from fiscal 2024.
- Alpha Cognition Inc. research and development expense for fiscal 2024 was $3.92M, a 19.73% decline from fiscal 2023.
- Alpha Cognition Inc. research and development expense for fiscal 2023 was $4.88M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.01M 10-Q · filed 2026-08-13 | $3.11M 10-Q · filed 2026-08-13 | $3.67M derived: sum of 3 quarters · filed 2026-08-13 | $4.25M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $1.10M 10-Q · filed 2026-05-14 | $1.67M derived: sum of 2 quarters · filed 2026-05-14 | $2.24M derived: sum of 3 quarters · filed 2026-05-14 | $2.65M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $569.75K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.14M derived: sum of 2 quarters · filed 2026-03-31 | $1.55M derived: sum of 3 quarters · filed 2026-08-13 | $1.87M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $573.59K 10-Q · filed 2025-11-13 | $979.73K derived: sum of 2 quarters · filed 2026-08-13 | $1.30M 10-Q · filed 2025-11-13 | $2.42M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $406.14K 10-Q · filed 2026-08-13 | $317.12K 10-Q · filed 2025-08-14 | $806.56K 10-Q · filed 2026-08-13 | $724.63K 10-Q · filed 2025-08-14 | $1.85M derived: sum of 3 quarters · filed 2026-08-13 | $2.84M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $400.42K 10-Q · filed 2026-05-14 | $407.51K 10-Q · filed 2025-05-15 | $1.44M derived: sum of 2 quarters · filed 2026-05-14 | $2.44M derived: sum of 3 quarters · filed 2026-05-14 | $3.40M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.04M derived: sum of 2 quarters · filed 2026-03-31 | $3.00M derived: sum of 3 quarters · filed 2026-03-31 | $3.92M 10-K · filed 2026-03-31 | $3.92M 10-K · filed 2025-03-31 | ||
| 2024-09-30 | $996.03K 10-Q · filed 2025-11-13 | $1.96M derived: sum of 2 quarters · filed 2025-11-13 | $2.88M 10-Q · filed 2025-11-13 | $3.99M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $967.20K 10-Q · filed 2025-08-14 | $1.88M 10-Q · filed 2025-08-14 | $2.99M derived: sum of 3 quarters · filed 2025-08-14 | $4.42M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $916.72K 10-Q · filed 2025-05-15 | $2.03M derived: sum of 2 quarters · filed 2025-05-15 | $3.46M derived: sum of 3 quarters · filed 2025-05-15 | $4.70M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.54M derived: sum of 2 quarters · filed 2025-03-31 | $3.79M derived: sum of 3 quarters · filed 2025-03-31 | $4.88M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $1.43M 10-Q · filed 2024-11-14 | $2.68M derived: sum of 2 quarters · filed 2024-11-14 | $3.77M 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | $1.25M 10-Q · filed 2024-08-12 | $2.34M 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |